ICIs targeting programmed cell death ligand-1 (PD-1), PD-L1, and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are currently the most advanced immunotherapies and have transformed the treatment paradigm for a variety of tumors, including lung cancer. Here, CTLA4 is linked to lung cancer.